Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
| Revenue (TTM) | $5.82B |
| Gross Profit (TTM) | $3.24B |
| EBITDA | $1.94B |
| Operating Margin | 41.90% |
| Return on Equity | 30.70% |
| Return on Assets | 16.80% |
| Revenue/Share (TTM) | $29.36 |
| Book Value | $31.57 |
| Price-to-Book | 4.05 |
| Price-to-Sales (TTM) | 4.32 |
| EV/Revenue | 3.645 |
| EV/EBITDA | 10.26 |
| Quarterly Earnings Growth (YoY) | 37.70% |
| Quarterly Revenue Growth (YoY) | 37.70% |
| Shares Outstanding | $202.70M |
| Float | $170.74M |
| % Insiders | 1.84% |
| % Institutions | 103.49% |
Volatility is currently contracting
The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.
Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INCY and any ticker you trade — then tracks every position and per-strategy win rate.
